Last reviewed · How we verify
IDP-118 High Strength
At a glance
| Generic name | IDP-118 High Strength |
|---|---|
| Also known as | IDP-118 |
| Sponsor | Dow Pharmaceutical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-118 High Strength CI brief — competitive landscape report
- IDP-118 High Strength updates RSS · CI watch RSS
- Dow Pharmaceutical Sciences portfolio CI